ABL pathway Biomarkers Consortium- Michael J Fox Foundation (2017 – 2019)

The ABL Pathway Biomarker Consortium is an MJFF-funded initiative to develop and validate assays appropriate for assessing the impact of c-Abl kinase inhibitors (e.g.,nilotinib) in clinical studies for Parkinson’s disease.


Hilal A. Lashuel, PhD, EPFL-Lausanne, Switzerland

Ted Dawson, Johns Hopkins University, USA

David R Walt, Tufts University, USA